Target type: biologicalprocess
The orderly movement of an astrocyte, a class of large neuroglial (macroglial) cells in the central nervous system, the largest and most numerous neuroglial cells in the brain and spinal cord. [CL:0000127, GOC:go_curators]
Astrocyte cell migration is a complex process involving a coordinated interplay of signaling pathways, cytoskeletal rearrangements, and interactions with the extracellular matrix. It is essential for proper brain development, wound healing, and responses to injury.
Here's a detailed breakdown of the process:
1. **Stimulus Recognition:** Astrocytes possess receptors that detect signals from their environment, including:
* **Neurotransmitters:** Astrocytes respond to neurotransmitters like glutamate and ATP, released by neurons.
* **Cytokines:** Inflammatory signals like TNF-α and IL-1β can trigger migration.
* **Extracellular Matrix Components:** Astrocytes interact with proteins like laminin and fibronectin in the extracellular matrix, which can influence their movement.
2. **Signal Transduction:** Receptor activation initiates intracellular signaling cascades that lead to changes in gene expression and protein activity:
* **Calcium Signaling:** Stimulation often causes a rise in intracellular calcium levels, which activates downstream signaling pathways.
* **MAP Kinase Pathway:** This pathway is involved in cell proliferation, survival, and migration.
* **PI3K/Akt Pathway:** This pathway is essential for cell survival and motility.
3. **Cytoskeletal Rearrangements:** Changes in the cytoskeleton, particularly actin and microtubules, are crucial for migration:
* **Actin Polymerization:** Actin filaments assemble at the leading edge of the migrating cell, forming protrusions called lamellipodia and filopodia.
* **Microtubule Dynamics:** Microtubules provide tracks for organelle transport and contribute to cell polarity.
4. **Adhesion and Detachment:** Astrocytes adhere to the extracellular matrix, and this adhesion needs to be regulated during migration:
* **Integrins:** These transmembrane proteins mediate cell adhesion and signaling.
* **Focal Adhesions:** These specialized structures form at the leading edge of the cell and anchor actin filaments to the extracellular matrix.
5. **Cell Polarization:** During migration, astrocytes develop a distinct polarity:
* **Leading Edge:** The front of the cell, where lamellipodia and filopodia extend.
* **Trailing Edge:** The rear of the cell, where the cell detaches from the substrate.
6. **Migration Mechanisms:** Astrocytes can migrate using different mechanisms, including:
* **Amoeboid Migration:** A relatively fast and less directional mode of migration involving the formation of pseudopodia.
* **Mesenchymal Migration:** A more directional mode of migration requiring cell adhesion and traction forces.
7. **Regulation of Migration:** Astrocyte migration is tightly regulated by various factors:
* **Growth Factors:** Factors like EGF and PDGF can stimulate astrocyte migration.
* **Chemotaxis:** Astrocytes can migrate toward specific chemical attractants, like neurotransmitters or chemokines.
* **Contact Guidance:** Astrocytes can migrate along specific pathways within the brain, guided by cues from the extracellular matrix.
8. **Functions of Astrocyte Migration:** Astrocyte migration plays critical roles in various physiological and pathological processes:
* **Brain Development:** Astrocytes migrate during embryogenesis to establish their proper positions in the brain.
* **Wound Healing:** Astrocytes migrate to sites of injury to promote repair and limit damage.
* **Neuroinflammation:** Astrocyte migration contributes to the inflammatory response in the brain.
* **Tumor Invasion:** Astrocytes can be involved in the spread of brain tumors.
9. **Clinical Implications:** Disruptions in astrocyte migration can contribute to various neurological disorders:
* **Neurodevelopmental Disorders:** Defects in astrocyte migration during development can lead to neurological disorders.
* **Neurodegenerative Diseases:** Astrocytes can migrate to areas of neuronal damage, contributing to disease progression.
* **Brain Tumors:** Aberrant astrocyte migration can contribute to the spread of brain tumors.
Astrocyte migration is a complex and multifaceted process with far-reaching implications for brain development, health, and disease. Understanding the mechanisms underlying astrocyte migration is crucial for developing new therapies for neurological disorders.'
"
Protein | Definition | Taxonomy |
---|---|---|
Nuclear receptor subfamily 2 group E member 1 | A nuclear receptor subfamily 2 group E member 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9Y466] | Homo sapiens (human) |
Matrix metalloproteinase-14 | A matrix metalloproteinase-14 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P50281] | Homo sapiens (human) |
C-C motif chemokine 2 | A C-C motif chemokine 2 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P13500] | Homo sapiens (human) |
Beta-hexosaminidase subunit beta | A beta-hexosaminidase subunit beta that is encoded in the genome of human. [PRO:DNx, UniProtKB:P07686] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
fasudil | fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia. fasudil: intracellular calcium antagonist; structure in first source | isoquinolines; N-sulfonyldiazepane | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent |
propafenone | propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias. Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. | aromatic ketone; secondary alcohol; secondary amino compound | anti-arrhythmia drug |
propranolol | propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3. Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. | naphthalenes; propanolamine; secondary amine | anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic |
pyrimethamine | Maloprim: contains above 2 cpds | aminopyrimidine; monochlorobenzenes | antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor |
dexpropranolol | propranolol | ||
tiludronic acid | tiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first source | organochlorine compound | |
epigallocatechin gallate | (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin. epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis) | flavans; gallate ester; polyphenol | antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite |
zoledronic acid | zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position. Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS. | 1,1-bis(phosphonic acid); imidazoles | bone density conservation agent |
tryptoline | tryptoline: neurotoxic factor that may be involved in development of Parkinson's disease; enzymatic prep from human brain converts tryptamine to tryptoline; RN given refers to parent cpd; structure | beta-carbolines | |
tadalafil | benzodioxoles; pyrazinopyridoindole | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent | |
marimastat | marimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide. marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary | hydroxamic acid; secondary carboxamide | antineoplastic agent; matrix metalloproteinase inhibitor |
2-acetamido-1,5-imino-1,2,5-trideoxy-d-glucitol | 2-acetamido-1,5-imino-1,2,5-trideoxy-D-glucitol: structure given in first source | ||
ilomastat | CS 610: matrix metalloproteinase inhibitor; structure in first source ilomastat : An N-acyl-amino acid obtained by formal condensation of the carboxy group of (2R)-2-[2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the amino group of N-methyl-L-tryptophanamide. A cell permeable broad-spectrum matrix metalloproteinase (MMP) inhibitor | hydroxamic acid; L-tryptophan derivative; N-acyl-amino acid | anti-inflammatory agent; antibacterial agent; antineoplastic agent; EC 3.4.24.24 (gelatinase A) inhibitor; neuroprotective agent |
n-desisopropylpropranolol | N-desisopropylpropranolol: RN given refers to parent cpd | ||
cgs 27023a | CGS 27023A: a matrix metalloproteinase inhibitor | ||
y 27632 | Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme. | aromatic amide | |
prinomastat | prinomastat : A hydroxamic acid that is (3S)-N-hydroxy-2,2-dimethylthiomorpholine-3-carboxamide in which the hydrogen attached to the thiomorpholine nitrogen has been replaced by a [4-(pyridin-4-yloxy)phenyl]sulfonyl group. It is a selective inhibitor with of matrix metalloproteinases (MMPs) 2, 3, 9, 13, and 14. prinomastat: a diazepine-based hydroxamic acid inhibitor; matrix metalloproteinase (MMP) inhibitor; angiogenesis inhibitor; | aromatic ether; hydroxamic acid; pyridines; sulfonamide; thiomorpholines | antineoplastic agent; EC 3.4.24.35 (gelatinase B) inhibitor; matrix metalloproteinase inhibitor |
ha 1100 | HA 1100: intracellular calcium antagonist | ||
rs-130830 | RS-130830: orally-active broad-spectrum matrix metalloproteinase inhibitor | ||
tmi-1 | |||
n-acetylglucosamine thiazoline | N-acetylglucosamine thiazoline: an analog of the oxazolinium bicyclic intermediate leading from N-acetylglucosamine to 1,6-anhydro-N-acetylmuramic acid | ||
batimastat | batimastat : A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor. batimastat: structure given in first source; a synthetic matrix metalloproteinase inhibitor | hydroxamic acid; L-phenylalanine derivative; organic sulfide; secondary carboxamide; thiophenes; triamide | angiogenesis inhibitor; antineoplastic agent; matrix metalloproteinase inhibitor |
ik 682 | IK 682: inhibits TNF-alpha converting enzyme; structure in first source | hydroxamic acid; pyrrolidin-2-ones; quinolines | |
epigallocatechin-3-o-(3''-o-methyl)-gallate | catechin | ||
ro 32-3555 | Ro 32-3555: structure given in first source | ||
sb 3ct compound | SB 3CT compound: a matrix metalloproteinase-2 inhibitor; structure in first source | aromatic ether | |
pd 166793 | |||
sc 78080 | |||
ro 31-9790 | Ro 31-9790: hydroxamic acid derivative | ||
incb3344 | INCB3344: potent and selective small molecule CCR2 chemokine receptor antagonist | ||
arp-100 | |||
kb r8301 | |||
N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide | N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide : A hydroxamic acid that is N-hydroxy-D-valinamide in which the alpha-amino group has been substituted by isopropoxy and [biphenyl]-4-ylsulfonyl groups. A selective matrix metalloproteinase-2 (MMP-2) inhibitor, it is one of the most potent inducers of autophagy. Its physiological roles include angiogenesis, cancer metastasis, embryogenesis, tissue remodeling in development, and wound healing. | D-valine derivative; hydroxamic acid | antineoplastic agent; autophagy inducer; EC 3.4.24.24 (gelatinase A) inhibitor; melanin synthesis inhibitor |
bms-566394 | BMS-566394: structure in first source | ||
incb3619 | INCB3619: ADAM inhibitor; structure in first source | ||
6-(3,5-difluoroanilino)-9-ethyl-2-purinecarbonitrile | 6-aminopurines | ||
6-(3,5-difluoroanilino)-9-(2,2-difluoroethyl)-2-purinecarbonitrile | 6-aminopurines | ||
9-(3,5-difluorophenyl)-6-(ethylamino)-2-purinecarbonitrile | imidazoles | ||
grassystatin a | grassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source | ||
thiamet g |